Catalent Signs Antibody Pact

Catalent Pharma Solutions has signed an agreement with PATH, an international nonprofit organization specializing in vaccines, drugs, diagnostics, devices, and system and services, to advance a project funded by the PATH Malaria Vaccine Initiative (MVI) by creating antibodies using Catalent Biologic’s cell-line technology.

Under the agreement, Catalent Biologics will employ its proprietary GPEx cell-line technology, coupled with an ambr workstation, which mimics the characteristics of traditional bioreactors at micro scale, to develop, optimize the process for expression, and manufacture antibodies under cGMP conditions at its Madison, Wisconsin facility, for further investigation by MVI and its partners.

Catalent’s GPEx technology creates mammalian cell lines that can be employed from early feasibility studies, to clinical manufacturing, through to commercial-scale production, according to Catalent. To date, seven GPEx-based antibody and protein products are approved and marketed, and 34 therapeutic candidates are currently in clinical development globally.

Source: Catalent Pharma Solutions

Leave a Reply

Your email address will not be published. Required fields are marked *